A machine-learning-selected P4 serum panel detects hepatocellular carcinoma and signals cirrhosis-to-cancer progression
A staged serum-proteomics study across 1,002 individuals used random-forest machine learning to select a four-marker panel, P4 (HABP2, CD163, AFP and PIVKA-II). In an independent validation set, the panel distinguished hepatocellular carcinoma from cirrhosis (AUC 0.979; sensitivity 0.925; specificity 0.915) and from healthy controls (AUC 0.992). In a prospective external cohort of cirrhosis patients followed for HCC, it predicted conversion with AUC 0.890 and median lead time of 11.4 months before imaging diagnosis.
Technology: Random-forest machine-learning model for serum-protein panel selection and HCC classification
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In an independent validation set, the panel distinguished hepatocellular carcinoma from cirrhosis (AUC 0.979; sensitivity 0.925; specificity 0.915) and from healthy controls (AUC 0.992). The prospectively collected cirrhosis cohort was split into 177 training and 76 validation participants for predictive-model construction; collection timing alone does not establish a prospective locked-model evaluation.
- Still unknown: The prospective cohort included 253 cirrhosis patients, with 36 developing HCC; 8 of 65 participants were false positives for conversion by the reported endpoint. This is source-reported research performance, not proof of improved survival or a clinically implemented screening test. The lead time is measured relative to imaging diagnosis in the study cohorts.
- AI role: The random-forest model evaluated serum protein panels and selected the four-marker P4 panel; researchers then tested classification in an independent validation set and assessed prediction of cirrhosis-to-HCC conversion in prospective follow-up data.
Evidence sources: https://www.nature.com/articles/s41467-023-44255-2.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 104 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.